Giselle Mosnaim, MD, an allergist and immunologist at Endeavor Health, discusses Rhapsido® (remibrutinib), a new FDA-approved oral therapy for chronic ...

The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

The approval was based on the C-POST study which evaluated cemiplimab in adults with CSCC at high risk of recurrence after surgery and radiation.

The risk for MASLD was significantly reduced by 14.7 and 13.5%, respectively, by replacing 330g/day of sugar-sweetened beverages or low- or non-sugar-sweetened beverages with water.

Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF.

The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.

Ambient trichloroethylene (TCE) is associated with an increased risk for Parkinson disease (PD), according to a study published online October 1 in Neurology. B ...

The same price is already available on Novo Nordisk’s direct-to-consumer website, as well as at Walmart and CVS.

Positivity decreased for 2vHPV, 4vHPV, and 9vHPV for vaccinated and unvaccinated participants from 2006 to 2023.

CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; ...

HealthDay News — The lifetime risk for heart failure has increased to 24%, according to a report published online September 22 in the Journal of Cardiac Failure.

The Food and Drug Administration (FDA) has expanded the approval of Simponi ® (golimumab) to include pediatric patients weighing at least 15kg with moderate to severely active ulcerative colitis (UC).